Efficacy and adherence of glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes mellitus in real-life settings - PubMed (original) (raw)
Review
. 2019 Dec;45(6):528-535.
doi: 10.1016/j.diabet.2019.01.006. Epub 2019 Jan 21.
Affiliations
- PMID: 30677504
- DOI: 10.1016/j.diabet.2019.01.006
Review
Efficacy and adherence of glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes mellitus in real-life settings
B Guerci et al. Diabetes Metab. 2019 Dec.
Abstract
Despite the availability of a large number of therapeutic options throughout the world, rates of optimal glycaemic control in adult patients with type 2 diabetes mellitus remain low. Delays in treatment intensification to insulin and low adherence to insulin regimes, which are well-documented contributors to poor glycaemic control, are in many cases driven by fear of hypoglycaemic events, weight gain and injections. Over the last 10 years, injectable glucagon-like peptide-1 receptor agonists (GLP1-RAs) have emerged as alternatives to basal insulin for treatment intensification in patients inadequately controlled with oral antidiabetic drugs. As a class, GLP1-RAs are associated with weight loss and fewer hypoglycaemic events than insulin. In addition, some of them are available in once-a-week formulations and therefore require fewer injections. However, as randomized controlled trials are not representative of everyday practice, physicians should consider the results of real-life studies to guide their treatment decisions. In this review, while significant variations in efficacy, tolerability and adherence data were noted from one study to another, rates of glycaemic control overall were low. Indeed, our present analysis has suggested that regular re-evaluations of treatment, including response, tolerability, adherence, cost and quality of life, are necessary.
Keywords: Adherence; Cost; Efficacy; Glucagon-like peptide-1 receptor agonists; Persistence; Type 2 diabetes mellitus.
Copyright © 2019. Published by Elsevier Masson SAS.
Similar articles
- Use of glucagon-like peptide-1 receptor agonists among individuals on basal insulin requiring treatment intensification.
Trautmann ME, Vora J. Trautmann ME, et al. Diabet Med. 2018 Jun;35(6):694-706. doi: 10.1111/dme.13610. Epub 2018 Mar 24. Diabet Med. 2018. PMID: 29478255 Free PMC article. Review. - Impact of delaying treatment intensification with a glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes uncontrolled on basal insulin: A longitudinal study of a US administrative claims database.
Tong L, Pan C, Wang H, Bertolini M, Lew E, Meneghini LF. Tong L, et al. Diabetes Obes Metab. 2018 Apr;20(4):831-839. doi: 10.1111/dom.13156. Epub 2017 Dec 4. Diabetes Obes Metab. 2018. PMID: 29119712 Free PMC article. - Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis.
Huthmacher JA, Meier JJ, Nauck MA. Huthmacher JA, et al. Diabetes Care. 2020 Sep;43(9):2303-2312. doi: 10.2337/dc20-0498. Diabetes Care. 2020. PMID: 32910778 - Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S. Waugh N, et al. Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Health Technol Assess. 2010. PMID: 20646668 Review. - User's guide to mechanism of action and clinical use of GLP-1 receptor agonists.
Shaefer CF Jr, Kushner P, Aguilar R. Shaefer CF Jr, et al. Postgrad Med. 2015;127(8):818-26. doi: 10.1080/00325481.2015.1090295. Epub 2015 Sep 15. Postgrad Med. 2015. PMID: 26371721 Review.
Cited by
- Comparative Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity or Overweight: A Systematic Review and Network Meta-Analysis.
Liu L, Shi H, Shi Y, Wang A, Guo N, Tao H, Nahata MC. Liu L, et al. Pharmaceuticals (Basel). 2024 Jun 24;17(7):828. doi: 10.3390/ph17070828. Pharmaceuticals (Basel). 2024. PMID: 39065679 Free PMC article. Review. - Combining Celiac and Hepatic Vagus Nerve Neuromodulation Reverses Glucose Intolerance and Improves Glycemic Control in Pre- and Overt-Type 2 Diabetes Mellitus.
Waataja JJ, Asp AJ, Billington CJ. Waataja JJ, et al. Biomedicines. 2023 Sep 4;11(9):2452. doi: 10.3390/biomedicines11092452. Biomedicines. 2023. PMID: 37760895 Free PMC article. - A Relative Cost of Control Analysis of IDegLira versus Other Forms of Basal Insulin Intensification in Mexico.
Garnica-Cuellar JC, Morales-Villegas E, López-Forero CA, Monroy-Cruz B, Pariti B, Deshwal S, Sekharan M, Osorio-Hernández M, García-Appendini IC. Garnica-Cuellar JC, et al. Pharmacoecon Open. 2023 Sep;7(5):841-849. doi: 10.1007/s41669-023-00421-2. Epub 2023 Jul 15. Pharmacoecon Open. 2023. PMID: 37452964 Free PMC article. - Clinical Characteristics Associated with Adherence and Persistence in Patients with Type 2 Diabetes Mellitus Treated with Dulaglutide.
Lee DSU, Lee H. Lee DSU, et al. J Diabetes Res. 2023 Jun 1;2023:7917641. doi: 10.1155/2023/7917641. eCollection 2023. J Diabetes Res. 2023. PMID: 37305431 Free PMC article. - Comparison of the Usability, Accuracy, Preference, and Satisfaction of Three Once-Weekly Glucagon-Like Peptide 1 Receptor Agonist Pen Devices in People With Type 2 Diabetes.
Wettergreen SA, Stewart MP, Kennedy K, Trujillo JM. Wettergreen SA, et al. Diabetes Spectr. 2023 Winter;36(1):5-13. doi: 10.2337/ds21-0108. Epub 2022 Jun 29. Diabetes Spectr. 2023. PMID: 36818408
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials